MX2020001820A - Metodos para reforzar las respuestas inmunitarias. - Google Patents

Metodos para reforzar las respuestas inmunitarias.

Info

Publication number
MX2020001820A
MX2020001820A MX2020001820A MX2020001820A MX2020001820A MX 2020001820 A MX2020001820 A MX 2020001820A MX 2020001820 A MX2020001820 A MX 2020001820A MX 2020001820 A MX2020001820 A MX 2020001820A MX 2020001820 A MX2020001820 A MX 2020001820A
Authority
MX
Mexico
Prior art keywords
methods
immune responses
boosting immune
relates
boosting
Prior art date
Application number
MX2020001820A
Other languages
English (en)
Inventor
Kumar Arora Ashwani
Weynants Vincent
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2020001820A publication Critical patent/MX2020001820A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones inmunogénicas, tales como vacunas, las cuales comprenden polipéptidos inmunogénicos a partir de Haemophilus influenzae y Moraxella catarrhalis, con el fin de utilizarse en métodos de refuerzo de una respuesta inmunitaria, y los métodos para el tratamiento a través del uso de los mismos. De una manera más particular, la invención se refiere al uso de estas composiciones inmunogénicas en los métodos para el tratamiento o la prevención de la exacerbación de la enfermedad pulmonar obstructiva crónica.
MX2020001820A 2017-08-14 2018-08-13 Metodos para reforzar las respuestas inmunitarias. MX2020001820A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545010P 2017-08-14 2017-08-14
US201862633263P 2018-02-21 2018-02-21
PCT/EP2018/071860 WO2019034575A1 (en) 2017-08-14 2018-08-13 METHODS OF AMPLIFYING IMMUNE RESPONSES

Publications (1)

Publication Number Publication Date
MX2020001820A true MX2020001820A (es) 2020-03-20

Family

ID=63350516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001820A MX2020001820A (es) 2017-08-14 2018-08-13 Metodos para reforzar las respuestas inmunitarias.

Country Status (8)

Country Link
US (1) US11723966B2 (es)
EP (1) EP3641808A1 (es)
JP (2) JP2020530478A (es)
CN (1) CN110996994A (es)
BR (1) BR112020001768A2 (es)
CA (1) CA3072018A1 (es)
MX (1) MX2020001820A (es)
WO (1) WO2019034575A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4009951A1 (en) * 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Process for preparing a composition comprising a protein d polypeptide
JP2024510717A (ja) * 2021-02-22 2024-03-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物、使用及び方法
WO2023194971A2 (en) * 2022-04-08 2023-10-12 St. Jude Children's Research Hospital Immunogenic compositions and methods for reducing transmission of pathogens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69327599T2 (de) 1992-06-25 2000-08-10 Smithkline Beecham Biolog Adjuvantien enthaltende Impfstoffzusammensetzung
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69740108D1 (de) * 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
AR022963A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
DE60132471T2 (de) 2000-09-26 2009-01-15 Idera Pharmaceuticals, Inc., Cambridge Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
KR20080042865A (ko) 2005-08-10 2008-05-15 아르네 포르스그렌 아베 모락셀라 카타랄리스와 상피세포, 세포외기질 단백질 및보체계의 상호작용
AU2007206114B2 (en) 2006-01-17 2013-01-24 Arne Forsgren A novel surface exposed Haemophilus influenzae protein (protein E; pE)
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
TW201620927A (zh) * 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途

Also Published As

Publication number Publication date
JP2023103380A (ja) 2023-07-26
EP3641808A1 (en) 2020-04-29
BR112020001768A2 (pt) 2020-09-29
CN110996994A (zh) 2020-04-10
US20200197504A1 (en) 2020-06-25
US11723966B2 (en) 2023-08-15
CA3072018A1 (en) 2019-02-21
WO2019034575A1 (en) 2019-02-21
JP2020530478A (ja) 2020-10-22

Similar Documents

Publication Publication Date Title
MX2016010954A (es) Construcciones de proteina superficial ubicua a2 y usos de las mismas.
ZA201905488B (en) Tigit- and light-based chimeric proteins
ZA202000373B (en) Anti-cd47 antibodies and uses thereof
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
MX2022003891A (es) Anticuerpos anti-muc16 y sus usos.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2021011949A (es) Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
EA201890355A1 (ru) Новые способы индукции иммунного ответа
WO2014113490A3 (en) Immunogenic wt-1 peptides and methods of use thereof
PH12018500578A1 (en) Methods of treating inflammatory diseases
WO2017027757A3 (en) Smallpox vaccine for use in cancer treatment
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
MX2020001820A (es) Metodos para reforzar las respuestas inmunitarias.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2016179034A3 (en) Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
MX2018005462A (es) Composiciones inmunogénicas de rsv quimérico y métodos de uso.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2018002901A (es) Proceso para preparar una vacuna tetravalente atenuada contra el dengue.
MX2022001488A (es) Composicion inmunogenica.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2022009171A (es) Composiciones para el tratamiento de dermatitis atopica canina y sus usos.
EP3510014A4 (en) COMPOSITIONS AND METHODS FOR USE OF GAMMA KETOALDEHYD CATCHERS FOR TREATING, PREVENTING OR IMPROVING NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD, OR DISEASES
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy